Published in final edited form as:

Regen Med. 2015 ; 10(6): 773–783. doi:10.2217/rme.15.41.

Induced Pluripotent Stem Cells: From Product-Focused Disease Modeling to Process-Focused Disease Discovery

Katherine A. Campbell^{a,b,c}, Andre Terzic^{a,b,d,e}, and Timothy J. Nelson^{a,b,c,f}

^aDepartment of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, Minnesota, USA

^bCenter for Regenerative Medicine, Mayo Clinic, Rochester, Minnesota, USA

^cDivision of General Internal Medicine, Mayo Clinic, Rochester, Minnesota, USA

^dDivision of Cardiovascular Diseases, Mayo Clinic, Rochester, Minnesota, USA

^eDepartment of Medical Genetics, Mayo Clinic, Rochester, Minnesota, USA

^fTransplant Center, Mayo Clinic, Rochester, Minnesota, USA

Summary

Induced pluripotent stem (iPS) cell technology offers an unprecedented opportunity to study patient-specific disease. This biotechnology platform enables recapitulation of individualized disease signatures in a dish through differentiation of patient-derived iPS cells. Beyond disease modeling, the *in vitro* process of differentiation toward genuine patient tissue offers a blueprint to inform disease etiology and molecular pathogenesis. Here, we highlight recent advances in patient-specific cardiac disease modeling and outline the future promise of iPS cell-based disease discovery applications.

Keywords

Induced Pluripotent Stem Cell; Disease Modeling; Disease Discovery; Cardiomyocyte; Channelopathy; Cardiomyopathy; Regenerative Medicine; Disease Pathogenesis

Introduction

Induced pluripotent stem (iPS) cells are a bioengineered cell type derived via nuclear reprogramming of somatic tissue into a pluripotent state. First described in mice [1] and shortly thereafter in humans [2, 3], iPS cells offer an unparalleled source of patient-specific, pluripotent stem cells that promise to advance next-generation diagnostic and clinical regenerative medicine [4, 5]. While the scalability and safety of iPS cell-based clinical applications remain under investigation [6], these cells increasingly provide an opportunity to target human cardiac diseases in a dish [7]. In fact, there has been significant progress using iPS cells as a platform for *in vitro* disease modeling, including a growing number of

examples of patient-specific models of channelopathies and cardiomyopathies [8–18]. The capacity of iPS cells to undergo differentiation into cardiac phenotypes enables the study of individualized disease processes in a highly controlled setting. Importantly, the proliferative nature of iPS cells provides an essentially unlimited pool of patient-specific cardiac progenitors and cardiomyocytes for investigation. Pharmacologic screens for novel therapeutic agents can now be conducted on functional human cardiomyocytes to serve as an individualized read-out of small molecule efficacy without risk of toxicity to the patient [19]. Here, we review the current progress in cardiac disease modeling applications and the future possibilities of cardiovascular disease discovery with patient-specific iPS cells.

Disease Modeling: Defining Cell-Autonomous Disease-in-a-Dish

As a benchmark to gauge the transformative potential of iPS cells, it is important to note that traditional disease diagnostic methods are typically linked to the pathophysiological context of the patient (Figure 1). Thus, clinical observations of disease are confounded by the mixture of disease-causing mechanisms and compensatory pathways. Without the ability to separate cause and effect, the current clinical paradigm may misconstrue compensatory mechanisms as contributors to disease etiology, or vice versa. However, through *in vitro* differentiation of iPS cells, we can now follow sequential cellular phenotypes from individual patients without the obstructive effects of surrounding physiology (Figure 1). Thus, iPS cell-based disease modeling enables a cell-autonomous perspective on pathogenic pathways without the confounding variables of tissue/organ/organism-based compensation.

Table 1 highlights recent disease modeling studies that use patient-derived iPS cells to model cardiac diseases and emphasizes the characteristics of cell phenotypes that were studied in each model. In these studies, patient-specific cardiomyocytes have been identified by a variety of gene and protein expression profiles, including sarcomeric proteins (ACTN2, MYH6, MYH7, MYL2, MYL7, TNNT2, TNNT3, TTN), cardiac transcription factors (ISL1, HAND-1, NKX2.5, GATA4, TBX5, NFATC4), calcium handling proteins (CACNA1C, CACNB2, PLN, RYR2, CASQ2, FKBP1B, CALM, CALR, SERCA, TRDN, JCTN), potassium ion channels (KCNQ1, KCNH1, KCNJ2, KCND3, KCNA5, KCNJ5, KCNE1, KCNJ3, KCNJ11, KCHIP2, KCNA4, KCNK2, HCN2, HCN4), sodium ion channels (SCN5A, SLC8A1), chloride channels (CLCN4), hormones (ANP), or other cardiomyocyte surface markers (ADRB1, ADRB2, CX43, VCAM1). It is important to note that all cardiovascular disease models highlighted herein have utilized contractile cardiomyocytes as the cell phenotype to recapitulate the signature of disease. While pure populations of iPS cell-derived cardiomyocytes remain difficult to efficiently and reliably generate via current methods of *in vitro* differentiation, the studies described below use a variety of cardiomyocyte markers to selectively study beating cardiac phenotypes *in vitro*.

iPS Cell Models of Cardiac Channelopathies

One of the first cardiac channelopathies modeled by iPS cells was Long QT Syndrome (LQTS), a disorder characterized by prolonged ventricular repolarization and increased propensity for polymorphic ventricular tachycardia [20]. Within 3 years of the initial description of human iPS cells [2, 3], a patient-specific model of Type 1 LQTS (R190Q

mutation in *KCNQ1*) was established [20]. In this study, dermal fibroblasts were isolated from related patients with LQTS1 and reprogrammed into iPS cells using retroviral vectors for *OCT3/4*, *SOX2*, *KLF4*, and *c-MYC*. Following nuclear reprogramming, patient-specific and healthy control iPS cells were differentiated into functional cardiomyocytes. Importantly, iPS cell-derived cardiomyocytes from LQTS1 patients recapitulated the electrophysiological signatures of disease (prolonged action potential duration and increased susceptibility to catecholaminergic arrhythmias) when compared to healthy controls. The power of this LQTS model is best realized in comparison to the limitations of established animal models of LQTS [16]. For example, differences in action potential characteristics, cardiomyocyte physiology, and heart rate between mouse and human hearts limit the informative nature of LQTS mouse models [16]. Establishing a patient-specific, cell-autonomous model of LQTS1 has been a breakthrough for the field of cardiac channelopathy research and is driving new paradigms for the pharmaceutical industry.

Similar disease models have recently been established of LQTS1 [21, 22], as well as LQTS2 (mutations in *KCNH2*) [23–26] and LQTS3 (mutations in *SCN5A*) [27, 28]. These studies have uniformly demonstrated that patient-specific iPS cell-derived cardiomyocytes can recapitulate disease electrophysiology. Specifically, prolonged action potential duration and increased propensity to drug-induced arrhythmias such as early after depolarizations have been observed in LQTS iPS cells. Pharmaceutical agents that modulate cardiac ion channel activity [21, 22, 24–28], allele specific RNA interference [23], and β adrenergic blocking agents [24, 26] have been employed to study the LQTS phenotype *in vitro*. Drug-screening of LQTS iPS cells provides a powerful resource to develop individualized clinical regimens for LQTS patients.

In addition to LQTS, patient-specific iPS cell models have also been described for Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT) [29–34]. While CPVT has two primary genetic causes, mutations in *RYR2* (CPVT1) or *CASQ2* (CPVT2), the arrhythmic disease phenotype is directly linked to abnormal calcium handling. Studies of CPVT patient-derived iPS cells have reproduced the arrhythmic signature of the disease in cardiomyocytes *in vitro*. Specifically, iPS cell-derived cardiomyocytes from CPVT patients display delayed after depolarizations, which are aggravated by catecholaminergic stress and rescued by *RYR2* blockers [32], *CaMKII* inhibitors [29], *SERCA* inhibitors, anti-arrhythmic agents, and β -blockers [30]. The capacity of CPVT patient-specific iPS cells to model the disease phenotype provides a strong platform with which to develop new drugs or optimize current treatment strategies for this disease.

Patient-specific iPS cell models have also been generated from additional cardiac channelopathies. As with studies of LQTS and CPVT, each cardiac channelopathy modeled by patient-derived iPS cells has focused on beating cardiomyocytes as the cellular phenotype to model disease (Table 1). Importantly, each patient-specific cardiac disease model has demonstrated the capacity to recapitulate cell-autonomous hallmarks of disease. For example, a decrease in sodium current density has been demonstrated in patient-specific iPS cell-derived cardiomyocytes with a sodium channel overlap syndrome [35]. iPS cells from patients with Jervell and Lange-Nielson Syndrome (JLNS) have documented prolonged action potential duration in differentiated cardiomyocytes compared to healthy

controls [36]. In iPS cell models of Timothy Syndrome, differentiated ventricular-like cardiomyocytes show prolonged action potential duration as well as excess calcium influx and abnormal calcium transients when compared to control cells [37]. Overall, iPS cell models of cardiac channelopathies have been successful in recapitulating the disease electrophysiology associated with known genetic defects.

iPS Cell Models of Cardiomyopathies

Cardiomyopathies have also been recently modeled *in vitro* with patient-specific iPS cells. One of the first cardiomyopathies modeled in patient-derived iPS cells was LEOPARD syndrome, a disorder most often caused by mutations in *PTPN11* and characterized by an increased incidence of hypertrophic cardiomyopathy [38]. In this study, LEOPARD patient-derived and healthy control iPS cells from an unaffected sibling were reprogrammed using *OCT3/4*, *SOX2*, *KLF4*, and *c-MYC* retroviral vectors. Following *in vitro* cardiac differentiation, LEOPARD iPS-cell derived cardiomyocytes had increased median cell surface area and nuclear localization of NFATC4 compared to healthy controls, which are indicative of a hypertrophic state. Levels of phosphorylated proteins were also analyzed to elucidate molecular differences between healthy and diseased iPS cell-derived cardiomyocytes. Interestingly, basal p-ERK levels were increased in LEOPARD iPS cells compared to healthy controls, though additional studies are required to determine if this early difference contributes to the development of hypertrophy in differentiated cardiomyocytes.

Additional cardiomyopathy models have been generated from patient-specific iPS cells with hypertrophic cardiomyopathy (HCM) [22, 39, 40]. Compared to healthy controls, iPS cell-derived cardiomyocytes from HCM patients showed increased cellular size, sarcomeric disorganization and greater nuclear localization of NFATC4, all signatures of a hypertrophic state. These HCM cardiomyocytes were also more sensitive to pharmacologically increased action potential duration and demonstrated a higher propensity for drug induced arrhythmias [22]. Another study described the aggravating influence of Endothelin 1 on the hypertrophic state of HCM iPS cell-derived cardiomyocytes. While this study saw fewer baseline differences between HCM and healthy control cardiomyocytes, the description of an extracellular factor that can modulate disease phenotype *in vitro* has advanced the study of HCM disease pathogenesis [40]. In a separate study of familial HCM, cardiomyocyte enlargement and contractile arrhythmia were linked to abnormal calcium dynamics in HCM cardiomyocytes. Specifically, abnormal calcium cycling and increased intracellular calcium levels could be pharmacologically modulated to reduce the hypertrophic characteristics of patient-derived cardiomyocytes *in vitro* [39]. Collectively, these studies document the capacity of iPS cell-derived cardiomyocytes to recapitulate HCM phenotypes, model clinical susceptibility to drug-induced cardiotoxicity, and screen for novel pharmaceutical agents or extracellular factors that modulate disease.

Similar disease models have also been documented using iPS cells from patients with dilated cardiomyopathy (DCM) [22, 41–43]. Studies of iPS cell-derived cardiomyocytes from DCM patients have highlighted disease characteristics such as sarcomeric disorganization, abnormal calcium handling, decreased contractility, and increased cellular stress in response

to β -adrenergic stimulation [22, 41]. In one study, iPS cells were derived from a DCM patient with a novel mutation in Desmin, an intermediate filament protein involved in cytoskeleton maintenance in cardiomyocytes. This study described abnormal calcium dynamics and impaired response to inotropic stress in patient-derived cardiomyocytes. Importantly, control iPS cells transduced with the mutant Desmin gene recapitulated disease phenotypes upon cardiac differentiation. This study highlights the capacity of iPS cells to functionally validate a suspected genetic cause of DCM [42]. Another study documents an increase in nuclear senescence and cellular apoptosis upon stimulating DCM iPS cell-derived cardiomyocytes with a field electrical stress [43]. Overall, cell-autonomous DCM phenotypes can be recapitulated using patient-specific iPS cells and *in vitro* differentiation into beating cardiomyocytes.

Recently, iPS cell models of arrhythmogenic right ventricular cardiomyopathy (ARVC) [44, 45], Barth Syndrome (BTHS) [46], Pompe Disease [47], and viral-induced cardiomyopathy [48] have also been described. *In vitro* models of ARVC have used iPS cell-derived cardiomyocytes from patients with mutations in *PKP2*. These studies have documented decreased and distorted expression of desmosomes on the cell surface and increased lipid droplet clusters in patient-derived cardiomyocytes versus healthy controls [44, 45]. The ability to aggravate the disease phenotype with adipogenic stimuli and mitigate the abnormalities with GSK3 β inhibition provides mechanistic insight into early ARVC disease pathogenesis [44]. Patient-specific models of BTHS, a mitochondrial disorder with associated cardiomyopathy, show typical disease characteristics such as abnormal sarcomere assembly, decreased cardiomyocyte contractility, and increased levels of reactive oxygen species [46]. Another recent *in vitro* model of cardiomyopathy used iPS cells derived from patients with Pompe disease [47]. In this study, iPS cells were generated from two patients with mutations in GAA and showed a glycogen storage defect in the pluripotent state. Interestingly, the nuclear reprogramming event was only successful following doxycycline-inducible rescue with a GAA transgene. In this way, autologous control cell lines were generated alongside of patient-specific diseased cell lines (demonstrated to have no transgene integration). Following *in vitro* differentiation into beating cardiomyocyte-like cells, the authors describe a more pronounced disease phenotype including increased glycogen levels, large glycogen storage vacuoles, and abnormal mitochondria. Notably, iPS cell models have also been generated for viral-induced cardiomyopathy [48]. This study investigated the infection of human iPS cell-derived cardiomyocytes with coxsackievirus B3 and demonstrated that this model could effectively predict antiviral drug efficacy and provide mechanistic insights into viral treatment strategies [48]. Collectively, these iPS cell models of diverse cardiomyopathies support the powerful capacity of patient-specific cellular platforms to recapitulate molecular signatures of disease.

In summary of the disease modeling studies reviewed herein, it is generally accepted that iPS cell technology offers a useful patient-specific platform to study cell-autonomous disease phenotypes *in vitro*. From Table 1, we point out that each patient-specific disease modeling study utilizes beating cardiomyocytes as the cellular phenotype to model disease. However, there is no consensus between the referenced studies as to what transcriptional or protein markers best characterize an iPS cell-derived cardiomyocyte or definitive markers of

maturity. This inconsistency in the field of iPS cell-based cardiac applications is acknowledged in a recent study that proposes a ratio of fetal to adult TNNI isoforms as a uniform measure of cardiomyocyte maturity across independent laboratories [49]. Indeed the reliability of generating cardiomyocytes of uniform maturation is a current challenge in the field and the caveat remains that iPS cell-derived cardiomyocytes often correspond to a fetal state [50]. While increased consistency in cardiomyocyte characterization would be a significant step forward, we propose that increased emphasis on the timeline of disease development during *in vitro* differentiation could further accelerate the field. In the following section, we highlight the advantages of disease discovery applications that focus on the process of cardiac differentiation in addition to the cardiomyocyte products.

Disease Discovery: Identifying the Initial Point of Disease Divergence

Beyond disease modeling applications, iPS cell technology also promises to advance the discovery of corrupted processes that underlie disease pathogenesis [51]. Harnessing the ability of iPS cells to transition through developmental stages *in vitro*, we can now shift our focus to the process of proper differentiation in addition to the end product of iPS-derived progeny (Figure 1). The dynamic transition from pluripotent stem cell to increasingly mature somatic tissue encompasses many intermediate progenitor stages. It is at these inflection points in the developmental timeline of iPS cell differentiation that we can now engage in discovery science. For the first time, the developmental roadmap of patient-specific congenital disease phenotypes can be deconvoluted through iPS cell differentiation. This process-oriented focus informs disease pathogenesis by pinpointing the initial divergence between health and disease. By mapping molecular profiles of progressive cellular stages, we can now identify the onset of molecular dysregulation prior to any cellular or organismal phenotype. While this process-focused approach may best serve discovery applications focused on congenital heart disease, a separate point of divergence may be identified that corresponds to late-onset adult cardiac phenotypes (Figure 2). In this way, iPS cells can inform the development of novel therapeutics that target the initial point of disease pathogenesis, whether in congenital or late-onset disease.

To emphasize the importance of process-focused disease discovery applications of iPS cells, a developmental view of health and disease is critical [51]. Rather than defining health and disease based on comparisons of mature cell phenotypes, we must strive to understand disease as a developmental process with a definable divergence point from health. Figure 2 defines health as the entire developmental timeline between Point A (pluripotent stem cell) and Point B (healthy mature cell). In contrast, congenital heart disease is defined as the entire pathway from Point A to Point C (diseased mature cell), with a discrete divergence point along the way. Similarly, late-onset adult cardiac disease is defined by the trajectory between Point B to Point C, with a separate divergence point between the two adult cell phenotypes. It is at these distinct divergence points between the dynamic processes of health and disease that we can identify disease pathogenesis. This temporal approach will enable precise interrogation of cellular dysfunction at early progenitor stages and the development of therapeutic strategies that target the pre-phenotypic manifestation of disease.

In the case of cardiovascular disease discovery, it is critical to understand the nature of the intermediate progenitor cells between the pluripotent state and the mature cardiomyocyte. A recent study of cardiac progenitors uncovers key transcriptional profiles that inform the staging of these cell types along a developmental timeline [52]. In this study, microarray analysis of murine cardiac-derived progenitor cells determined unique transcriptional signatures across different cell types. Based on the expression levels of known stemness or cardiomyocyte-specific genes, the authors staged the progenitor cells according to their level of cardiac commitment. From earliest (least cardiac committed) to latest (most cardiac committed), the progenitor stages are: *ckit*⁺ cells, side population cells, and *Sca1*⁺ cells [52]. As evidenced by this study, there are defined cellular stages within the healthy mouse heart. Recently, single-cell transcriptional profiles were also described for early embryonic cardiomyocytes and mES cell-derived cardiac progenitor cells and cardiomyocytes [53]. This study further refines our understanding of cardiac lineages within the embryo and those generated from *in vitro* differentiation. As these studies demonstrate, it is critical to understand the developmental stages of normal cardiogenesis in order to calibrate future disease discovery efforts to a defined timeline. Moreover, a standardized roadmap of normal heart development is critical to inform temporal studies of disease pathogenesis using iPS cells.

Recent Progress in Cardiac Disease Discovery

Toward the goal of defining the molecular timeline of heart development, recent studies describe a transcriptional atlas of normal cardiogenesis from the pluripotent state to adult cardiomyocytes [54, 55]. In these studies, authors map the dynamic transcriptional landscape of murine heart development from an unbiased genomic perspective. Through time-course transcriptome analysis, they describe the first comprehensive map of gene expression from embryonic stem cells to adult ventricular tissue. These studies also interrogated spatial transcriptional patterns between left ventricle (LV) and right ventricle (RV) development. Interestingly, the authors highlight a greater transcriptional divergence between temporal stages of cardiac development than between distinct LV and RV structures. These data indicate that differences in ventricular tissue may depend on post-translational modifications or changes induced by mechanical stress. As current cardiac differentiation protocols often generate mixed populations of right and left ventricular cardiomyocytes, insight into subpopulation specification could greatly advance both cardiac disease modeling and disease discovery application of iPS cells [50].

Additionally, the unbiased generation of a transcriptional atlas of cardiac development identified greater complexity in dynamic transcriptional networks during normal cardiogenesis than previously appreciated [54]. From the vast numbers of genes that change during heart development, a disease-centric dynamic interactome has been established based on known genetic variants in congenital heart diseases (CHD) [54]. This critical filter enabled identification of stage-specific regulatory networks and hubs that underlie the pathogenesis of CHD. Importantly, these datasets provide a natural context of heart development to better uncover the balance between health and disease. Disease discovery efforts focused on congenital cardiac disease can now be oriented according to an embryo-defined roadmap of cardiogenesis and informed by the dynamic nature of native

developmental signatures. By providing a benchmark of normal cardiac development, this transcriptional atlas of cardiogenesis can gauge ongoing studies of cardiac pathogenesis. Overall, these studies provide a developmental context in which to calibrate future *in vitro* studies of cardiac disease development and progression. Recently, this temporal framework has been harnessed in a study of Rbm20-linked DCM [56]. This disease-discovery investigation utilized the dynamic transcriptional profiles of normal cardiac development to inform a stage-wise, mechanistic model of DCM onset.

In this study [56], authors knocked down Rbm20, an RNA binding protein that functions in cardiac transcript splicing. As mutations in Rbm20 are associated with an early onset cardiomyopathic phenotype, they hypothesized a critical role of Rbm20 in embryonic heart development. Through the use of a high-throughput pluripotent model system and unbiased RNA sequencing analysis, this study identified an early point of transcriptional divergence (D12 of cardiac differentiation) that preceded the cellular phenotype (D24) in mES cell-derived cardiomyocytes. The divergent molecular signature identified differential expression of key cardiac genes including Nkx2.5 and Tnnt2 as well as aberrant splicing of Mef2a and Relb. These findings indicate an initial dysregulation in RNA-processing of cardiac transcription factors and aberrant expression of cardiac gene networks prior to phenotypic onset of disease. Thus, the authors provide evidence that a pluripotent stem cell platform can uncover initial signatures of disease pathogenesis.

Within the same mES cell model of Rbm20-linked DCM, authors discovered differential expression of extracellular matrix (ECM) genes, previously noted in physiological models of DCM but believed to be compensatory in nature. This study suggests that the change in ECM gene expression may be independent of physiological compensation and more directly related to the molecular etiology of Rbm20-linked DCM. Herein, we see the powerful capacity of *in vitro* disease models to distinguish between cell-autonomous drivers of phenotype and physiological adaptation to disease. This important distinction enables researchers to tease apart molecular mechanisms of disease pathogenesis in the absence of confounding physiological compensation. Overall, this study highlights the developmental nature of Rbm20-linked DCM as a disease that is patterned during early cardiogenesis and progressively unravels due to pathogenic cardiac remodeling. Additional studies of this nature are required to accelerate our understanding of progenitor cell contribution to disease and inform the development of novel therapeutic strategies that target earlier stages of disease.

Challenges in iPS Cell Disease Modeling and Disease Discovery

While significant progress is continuing to be made using iPS cells as a platform for cardiac disease modeling and disease discovery, the field remains limited by challenges in both the reprogramming and differentiation phases of these experiments [50]. Future advances in disease modeling and disease discovery studies will require greater predictability and consistency in cardiac differentiation of individual iPS cell lines. Moreover, increased specificity in cardiomyocyte subtype differentiation and the generation of mature cardiomyocyte phenotypes will be necessary to unravel precise mechanisms of late-onset disease pathogenesis. In addition, improvements in the scalability of *in vitro* cardiac

differentiation will accelerate high-throughput drug screening applications of iPS cell-derived cardiomyocytes.

Differences in nuclear reprogramming strategy, including the identity of pluripotency transgenes and the integrating or non-integrating nature of transduction, can significantly variegate iPS cell cardiogenicity [57–59]. Moreover, residual epigenetic signatures of the starting material may introduce differentiation bias toward a cellular phenotype more closely related to the somatic origin [60–62]. Further complexity is added by the clonal variability in cardiogenic capacity [59] that exists across iPS cell lines from an individual patient even when reprogramming strategy and somatic origin are held constant. Additional research must be conducted to determine the optimal somatic origin and reprogramming strategy to yield consistent and reliable differentiation output from iPS cells.

The heterogeneous nature of iPS cell-derived cardiomyocytes is also a significant limitation of current cardiac disease modeling and disease discovery applications. Variability in the percentage of cardiac tissue within an iPS cell-derived population [50, 59] reveals the current challenge of efficient and reliable cardiac differentiation. In addition, within the cardiac population of cells, there is often an unpredictable mix of cardiomyocyte subtypes: atrial, ventricular, and nodal [50]. Recent work has been conducted to modulate cellular signaling during cardiac differentiation and regulate the ratio of resulting atrial/ventricular to nodal cardiomyocytes [63]. Additional studies will be necessary for researchers to gain the precise control needed to study specific cardiomyocyte subtypes *in vitro*.

Insights gained from iPS cell models of disease are also affected by the limited maturation of iPS cell-derived cardiomyocytes. Most often, *in vitro* cardiomyocytes only achieve a fetal phenotype in contractile machinery and electrophysiological properties [50]. While recent work has highlighted factors such as mechanical force that can induce sarcomeric maturity within iPS cell-derived cardiomyocytes [64], much more research is needed to consistently generate adult-like cardiomyocytes *in vitro*. To advance process-focused disease discovery applications, additional studies will be required to determine the accuracy with which iPS cell-derived cardiac progenitors align with natural progenitor stages during *in utero* heart development [55].

Furthermore, advances in drug screening applications of iPS cell-derived cardiomyocytes will require the development of differentiation protocols that are scalable to high-throughput production. Recent advances in suspension culture of iPS cells enable expansion of high-quality undifferentiated cells beyond the limits of traditional adherent cell culture [65]. In addition, progress in electrophysiological assays using multielectrode arrays now enables reliable and high-throughput readouts for *in vitro* drug screening using iPS cell-derived cardiomyocytes [66]. Overall, while recent and ongoing studies have greatly advanced the specificity and reproducibility of iPS cell-based cardiac differentiation, much work remains to be done to optimize the generation of *in vitro* cardiomyocytes for disease modeling and disease discovery applications.

Future Perspective

As the field of bioengineered stem cells continues to advance, there is particular excitement for increased focus on the process of *in vitro* differentiation to complement studies of the final cell phenotype. In this way, the field can harness the full potential of iPS cells to uncover the initial pathogenesis of cardiac disease. The individualized nature of this disease discovery platform enables for the first time visualization of patient-specific, cell-autonomous disease development. This evolution from product-focused disease modeling to further encompass process-focused disease discovery brings the opportunity to better understand pre-phenotypic disease onset and lays the groundwork for targeted individualized therapeutics. We can thereby envision a transformation of clinical practice wherein preventative *in utero* therapeutics will target causative molecular defects that underlie disease pathogenesis.

Acknowledgments

Funding Sources

This work was supported by an American Heart Association Predoctoral Fellowship (14PRE20380241), the Mayo Clinic Center for Regenerative Medicine, and the Todd and Karen Wanek Family Program for Hypoplastic Left Heart Syndrome.

Bibliography

Papers of special note have been highlighted as:

* of interest

** of considerable interest

1. Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. *Cell*. 2006; 126:663–676. [PubMed: 16904174]
2. Yu J, Vodyanik MA, Smuga-Otto K, Antosiewicz-Bourget J, Frane JL, Tian S, et al. Induced Pluripotent Stem Cell Lines Derived from Human Somatic Cells. *Science*. 2007; 318:1917–1920. [PubMed: 18029452]
3. Takahashi K, Tanabe K, Ohnuki M, Narita M, Ichisaka T, Tomoda K. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. *Cell*. 2007; 131:861–872. [PubMed: 18035408]
4. Inoue H, Nagata N, Kurokawa H, Yamanaka S. iPS cells: a game changer for future medicine. *EMBO J*. 2014; 33:409–417. [PubMed: 24500035]
5. Nelson TJ, Terzic A. Induced pluripotent stem cells: an emerging theranostics platform. *Clin Pharmacol Ther*. 2011; 89:648–650. [PubMed: 21512525]
6. Prowse ABJ, Timmins NE, Yau TM, Li R-K, Weisel RD, Keller G, et al. Transforming the Promise of Pluripotent Stem Cell-Derived Cardiomyocytes to a Therapy: Challenges and Solutions for Clinical Trials. *Can J Cardiol*. 2014; 30:1335–1349. [PubMed: 25442434]
7. Terzic A, Nelson TJ. Regenerative Medicine Primer. *Mayo Clin Proc*. 2013; 88:766–775. [PubMed: 23809322]
8. Trounson A, Shepard KA, DeWitt ND. Human disease modeling with induced pluripotent stem cells. *Curr Opin Genet Dev*. 2012; 22:509–516. [PubMed: 22868174]
9. Onder TT, Daley GQ. New lessons learned from disease modeling with induced pluripotent stem cells. *Curr Opin Genet Dev*. 2012; 22:500–508. [PubMed: 22749051]
10. Ebert AD, Liang P, Wu JC. Induced Pluripotent Stem Cells as a Disease Modeling and Drug Screening Platform. *J Cardiovasc Pharmacol*. 2012; 60:408–416. [PubMed: 22240913]

11. Egashira T, Yuasa S, Fukuda K. Novel Insights into Disease Modeling Using Induced Pluripotent Stem Cells. *Biol Pharm Bull.* 2013; 36:182–188. [PubMed: 23370349]
12. Suh CY, Wang Z, Bártulos O, Qyang Y. Advancements in Induced Pluripotent Stem Cell Technology for Cardiac Regenerative Medicine. *J Cardiovasc Pharmacol Ther.* 2014; 19:330–339. [PubMed: 24651517]
13. Zanella F, Lyon RC, Sheikh F. Modeling heart disease in a dish: From somatic cells to disease-relevant cardiomyocytes. *Trends Cardiovasc Med.* 2014; 24:32–44. [PubMed: 24054750]
14. Matsa E, BurrIDGE PW, Wu JC. Human Stem Cells for Modeling Heart Disease and for Drug Discovery. *Sci Transl Med.* 2014; 6:1–6.
15. Sharma A, Wu JC, Wu SM. Induced pluripotent stem cell-derived cardiomyocytes for cardiovascular disease modeling and drug screening. *Stem Cell Res Ther.* 2013; 4:150–158. [PubMed: 24476344]
16. Li G, Cheng G, Wu J, Ma S, Sun C. New iPSC for old long QT syndrome modeling: Putting the evidence into perspective. *Exp Biol Med (Maywood).* 2014; 239:131–140. [PubMed: 24363251]
17. Karakikes I, Termglinchan V, Wu JC. Human-induced pluripotent stem cell models of inherited cardiomyopathies. *Curr Opin Cardiol.* 2014; 29:214–219. [PubMed: 24576884]
18. Zhao Q, Cai H, Zhan Y, Li B, Hu S, Sun N. Applications of human-induced pluripotent stem cells in the investigation of inherited cardiomyopathy. *Int J Cardiol.* 2014; 177:604–606. [PubMed: 25286769]
19. Matsa E, Sallam K, Wu JC. Cardiac Stem Cell Biology: Glimpse of the Past, Present, and Future. *Circ Res.* 2014; 114:21–27. [PubMed: 24385505]
20. Moretti A, Bellin M, Welling A, Jung CB, Lam JT, Bott-Flügel L, et al. Patient-specific induced pluripotent stem-cell models for long-QT syndrome. *N Engl J Med.* 2010; 363:1397–1409. [PubMed: 20660394]
21. Egashira T, Yuasa S, Suzuki T, Aizawa Y, Yamakawa H, Matsuhashi T, et al. Disease characterization using LQTS-specific induced pluripotent stem cells. *Cardiovasc Res.* 2012; 95:419–429. [PubMed: 22739119]
22. Liang P, Lan F, Lee AS, Gong T, Sanchez-Freire V, Wang Y, et al. Drug Screening Using a Library of Human Induced Pluripotent Stem Cell–Derived Cardiomyocytes Reveals Disease-Specific Patterns of Cardiotoxicity. *Circulation.* 2013; 127:1677–1691. [PubMed: 23519760]
23. Matsa E, Dixon JE, Medway C, Georgiou O, Patel MJ, Morgan K, et al. Allele-specific RNA interference rescues the long-QT syndrome phenotype in human-induced pluripotency stem cell cardiomyocytes. *Eur Heart J.* 2014; 35:1078–1087. [PubMed: 23470493]
24. Matsa E, Rajamohan D, Dick E, Young L, Mellor I, Staniforth A, et al. Drug evaluation in cardiomyocytes derived from human induced pluripotent stem cells carrying a long QT syndrome type 2 mutation. *Eur Heart J.* 2011; 32:952–962. [PubMed: 21367833]
25. Itzhaki I, Maizels L, Huber I, Zwi-Dantsis L, Caspi O, Winterstern A, et al. Modelling the long QT syndrome with induced pluripotent stem cells. *Nature.* 2011; 471:225–229. [PubMed: 21240260]
26. Lahti AL, Kujala VJ, Chapman H, Koivisto A-P, Pekkanen-Mattila M, Kerkelä E, et al. Model for long QT syndrome type 2 using human iPS cells demonstrates arrhythmogenic characteristics in cell culture. *Dis Model Mech.* 2012; 5:220–230. [PubMed: 22052944]
27. Ma D, Wei H, Zhao Y, Lu J, Li G, Sahib NBE, et al. Modeling type 3 long QT syndrome with cardiomyocytes derived from patient-specific induced pluripotent stem cells. *Int J Cardiol.* 2013; 168:5277–5286. [PubMed: 23998552]
28. Terrenoire C, Wang K, Chan Tung KW, Chung WK, Pass RH, Lu JT, et al. Induced pluripotent stem cells used to reveal drug actions in a long QT syndrome family with complex genetics. *J Gen Physiol.* 2013; 141:61–72. [PubMed: 23277474]
29. Di Pasquale E, Lodola F, Miragoli M, Denegri M, Avelino-Cruz JE, Buonocore M, et al. CaMKII inhibition rectifies arrhythmic phenotype in a patient-specific model of catecholaminergic polymorphic ventricular tachycardia. *Cell Death Dis.* 2013; 4:1–11.
30. Itzhaki I, Maizels L, Huber I, Gepstein A, Arbel G, Caspi O, et al. Modeling of catecholaminergic polymorphic ventricular tachycardia with patient-specific human-induced pluripotent stem cells. *J Am Coll Cardiol.* 2012; 60:990–1000. [PubMed: 22749309]

31. Fatima A, Xu G, Shao K, Papadopoulos S, Lehmann M, Arnáiz-Cot JJ, et al. In vitro Modeling of Ryanodine Receptor 2 Dysfunction Using Human Induced Pluripotent Stem Cells. *Cell Physiol Biochem*. 2011; 28:579–592. [PubMed: 22178870]
32. Jung CB, Moretti A, Mederos y Schnitzler M, Iop L, Storch U, Bellin M, et al. Dantrolene rescues arrhythmogenic RYR2 defect in a patient-specific stem cell model of catecholaminergic polymorphic ventricular tachycardia. *EMBO Mol Med*. 2012; 4:180–191. [PubMed: 22174035]
33. Kujala K, Paavola J, Lahti A, Larsson K, Pekkanen-Mattila M, Viitasalo M, et al. Cell Model of Catecholaminergic Polymorphic Ventricular Tachycardia Reveals Early and Delayed Afterdepolarizations. *PLoS ONE*. 2012; 7:e44660. [PubMed: 22962621]
34. Novak A, Barad L, Zeevi-Levin N, Shick R, Shtrichman R, Lorber A, et al. Cardiomyocytes generated from CPVTD307H patients are arrhythmogenic in response to β -adrenergic stimulation. *J Cell Mol Med*. 2012; 16:468–482. [PubMed: 22050625]
35. Davis RP, Casini S, van den Berg CW, Hoekstra M, Remme CA, Dambrot C, et al. Cardiomyocytes Derived From Pluripotent Stem Cells Recapitulate Electrophysiological Characteristics of an Overlap Syndrome of Cardiac Sodium Channel Disease/Clinical Perspective. *Circulation*. 2012; 125:3079–3091. [PubMed: 22647976]
36. Zhang M, D'Aniello C, Verkerk AO, Wrobel E, Frank S, Ward-van Oostwaard D, et al. Recessive cardiac phenotypes in induced pluripotent stem cell models of Jervell and Lange-Nielsen syndrome: Disease mechanisms and pharmacological rescue. *Proc Natl Acad Sci USA*. 2014; 111:E5383–E5392. [PubMed: 25453094]
37. Yazawa M, Hsueh B, Jia X, Pasca AM, Bernstein JA, Hallmayer J, et al. Using induced pluripotent stem cells to investigate cardiac phenotypes in Timothy syndrome. *Nature*. 2011; 471:230–234. [PubMed: 21307850]
38. Carvajal-Vergara X. Patient-specific induced pluripotent stem-cell-derived models of LEOPARD syndrome. *Nature*. 2010; 465:808–812. [PubMed: 20535210]
39. Lan F, Lee AS, Liang P, Sanchez-Freire V, Nguyen PK, Wang L, et al. Abnormal Calcium Handling Properties Underlie Familial Hypertrophic Cardiomyopathy Pathology in Patient-Specific Induced Pluripotent Stem Cells. *Cell Stem Cell*. 2013; 12:101–113. [PubMed: 23290139]
40. Tanaka A, Yuasa S, Mearini G, Egashira T, Seki T, Kodaira M, et al. Endothelin-1 Induces Myofibrillar Disarray and Contractile Vector Variability in Hypertrophic Cardiomyopathy–Induced Pluripotent Stem Cell–Derived Cardiomyocytes. *J Am Heart Assoc*. 2014; 3:e001263. [PubMed: 25389285]
41. Sun N, Yazawa M, Liu J, Han L, Sanchez-Freire V, Abilez OJ, et al. Patient-specific induced pluripotent stem cells as a model for familial dilated cardiomyopathy. *Sci Transl Med*. 2012; 4:130–147.
42. Tse H-F, Ho JCY, Choi S-W, Lee Y-K, Butler AW, Ng K-M, et al. Patient-specific induced-pluripotent stem cells-derived cardiomyocytes recapitulate the pathogenic phenotypes of dilated cardiomyopathy due to a novel DES mutation identified by whole exome sequencing. *Hum Mol Genet*. 2013; 22:1395–1403. [PubMed: 23300193]
43. Siu C-W, Lee Y-K, Ho JC-Y, Lai W-H, Chan Y-C, Ng K-M, et al. Modeling of lamin A/C mutation premature cardiac aging using patient-specific induced pluripotent stem cells. *Aging (Albany NY)*. 2012; 4:803–822. [PubMed: 23362510]
44. Caspi O, Huber I, Gepstein A, Arbel G, Maizels L, Boulos M, et al. Modeling of Arrhythmogenic Right Ventricular Cardiomyopathy With Human Induced Pluripotent Stem Cells. *Circ Cardiovasc Genet*. 2013; 6:557–568. [PubMed: 24200905]
45. Ma D, Wei H, Lu J, Ho S, Zhang G, Sun X, et al. Generation of patient-specific induced pluripotent stem cell-derived cardiomyocytes as a cellular model of arrhythmogenic right ventricular cardiomyopathy. *Eur Heart J*. 2013; 34:1122–1133. [PubMed: 22798562]
46. Wang G, McCain ML, Yang L, He A, Pasqualini FS, Agarwal A, et al. Modeling the mitochondrial cardiomyopathy of Barth syndrome with induced pluripotent stem cell and heart-on-chip technologies. *Nat Med*. 2014; 20:616–623. [PubMed: 24813252]
47. Huang H-P, Chen P-H, Hwu W-L, Chuang C-Y, Chien Y-H, Stone L, et al. Human Pompe disease-induced pluripotent stem cells for pathogenesis modeling, drug testing and disease marker identification. *Hum Mol Genet*. 2011; 20:4851–4864. [PubMed: 21926084]

48. Sharma A, Marceau C, Hamaguchi R, Burridge PW, Rajarajan K, Churko JM, et al. Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes as an In Vitro Model for Coxsackievirus B3-Induced Myocarditis and Antiviral Drug Screening Platform. *Circ Res.* 2014; 115:556–566. [PubMed: 25015077]
49. Bedada Fikru B, Chan Sunny S-K, Metzger Stefania K, Zhang L, Zhang J, Garry Daniel J, et al. Acquisition of a Quantitative, Stoichiometrically Conserved Ratiometric Marker of Maturation Status in Stem Cell-Derived Cardiac Myocytes. *Stem Cell Reports.* 2014; 3:594–605. [PubMed: 25358788]
50. Burridge Paul W, Keller G, Gold Joseph D, Wu Joseph C. Production of De Novo Cardiomyocytes: Human Pluripotent Stem Cell Differentiation and Direct Reprogramming. *Cell Stem Cell.* 2012; 10:16–28. [PubMed: 22226352]
51. Nelson TJ, Martinez-Fernandez A, Terzic A. Induced pluripotent stem cells: developmental biology to regenerative medicine. *Nat Rev Cardiol.* 2010; 7:700–710. [PubMed: 20956984]
52. Dey D, Han L, Bauer M, Sanada F, Oikonomopoulos A, Hosoda T, et al. Dissecting the Molecular Relationship Among Various Cardiogenic Progenitor Cells. *Circ Res.* 2013; 112:1253–1262. [PubMed: 23463815]
53. Li G, Plonowska K, Kuppusamy R, Sturzu A, Wu SM. Identification of cardiovascular lineage descendants at single-cell resolution. *Development.* 2015; 142:846–857. [PubMed: 25633351]
54. Li X, Martinez-Fernandez A, Hartjes KA, Kocher J-PA, Olson TM, Terzic A, et al. Transcriptional atlas of cardiogenesis maps congenital heart disease interactome. *Physiol Genomics.* 2014; 46:482–495. [PubMed: 24803680]
55. Martinez-Fernandez A, Li X, Hartjes KA, Terzic A, Nelson TJ. Natural Cardiogenesis-Based Template Predicts Cardiogenic Potential of Induced Pluripotent Stem Cell Lines. *Circ Cardiovasc Genet.* 2013; 6:462–471. [PubMed: 24036272]
56. Beraldi R, Li X, Martinez Fernandez A, Reyes S, Secreto F, Terzic A, et al. Rbm20-deficient cardiogenesis reveals early disruption of RNA processing and sarcomere remodeling establishing a developmental etiology for dilated cardiomyopathy. *Hum Mol Genet.* 2014; 23:3779–3791. [PubMed: 24584570]
57. Martinez-Fernandez A, Nelson T, Ikeda Y, Terzic A. c-MYC-Independent Nuclear Reprogramming Favors Cardiogenic Potential of Induced Pluripotent Stem Cells. *J Cardiovasc Transl Res.* 2010; 3:13–23. [PubMed: 20221419]
58. Martinez-Fernandez A, Nelson T, Terzic A. Nuclear Reprogramming Strategy Modulates Differentiation Potential of Induced Pluripotent Stem Cells. *J Cardiovasc Transl Res.* 2011; 4:131–137. [PubMed: 21207217]
59. Hartjes KA, Li X, Martinez-Fernandez A, Roemmich AJ, Larsen BT, Terzic A, et al. Selection Via Pluripotency-Related Transcriptional Screen Minimizes the Influence of Somatic Origin on iPSC Differentiation Propensity. *STEM CELLS.* 2014; 32:2350–2359. [PubMed: 24802033]
60. Kim K, Doi A, Wen B, Ng K, Zhao R, Cahan P, et al. Epigenetic memory in induced pluripotent stem cells. *Nature.* 2010; 467:285–290. [PubMed: 20644535]
61. Polo JM, Liu S, Figueroa ME, Kulalert W, Eminli S, Tan KY. Cell type of origin influences the molecular and functional properties of mouse induced pluripotent stem cells. *Nat Biotechnol.* 2010; 28:848–855. [PubMed: 20644536]
62. Ohi Y, Qin H, Hong C, Blouin L, Polo JM, Guo T, et al. Incomplete DNA methylation underlies a transcriptional memory of somatic cells in human iPS cells. *Nat Cell Biol.* 2011; 13:541–549. [PubMed: 21499256]
63. Zhu W-Z, Xie Y, Moyes KW, Gold JD, Askari B, Laflamme MA. Neuregulin/ErbB Signaling Regulates Cardiac Subtype Specification in Differentiating Human Embryonic Stem Cells. *Circ Res.* 2010; 107:776–786. [PubMed: 20671236]
64. Tulloch NL, Muskheli V, Razumova MV, Korte FS, Regnier M, Hauch KD, et al. Growth of Engineered Human Myocardium With Mechanical Loading and Vascular Coculture. *Circ Res.* 2011; 109:47–59. [PubMed: 21597009]
65. Amit M, Laevsky I, Miropolsky Y, Shariki K, Peri M, Itskovitz-Eldor J. Dynamic suspension culture for scalable expansion of undifferentiated human pluripotent stem cells. *Nat Protocols.* 2011; 6:572–579. [PubMed: 21527915]

66. Harris K, Aylott M, Cui Y, Louttit JB, McMahon NC, Sridhar A. Comparison of Electrophysiological Data From Human-Induced Pluripotent Stem Cell-Derived Cardiomyocytes to Functional Preclinical Safety Assays. *Toxicological Sciences*. 2013; 134:412–426. [PubMed: 23690542]

Executive Summary

Product-Focused Disease Modeling

- Various cardiac channelopathies and cardiomyopathies have been successfully modeled *in vitro* using beating iPS cell-derived cardiomyocytes from diseased patients.
- Patient-specific iPS cell platforms are currently being utilized to study the cell-autonomous nature of disease and recapitulate disease phenotypes at the cellular level.
- Direct comparison between iPS cell-derived cardiomyocytes from patients and controls can identify an individualized signature of disease.

Process-Focused Disease Discovery

- The process of *in vitro* differentiation can be studied to pinpoint the initial molecular divergence between health and disease.
- A transcriptional atlas of normal cardiogenesis can inform temporal studies of cardiac disease pathogenesis.
- Identification of the initial point of disease pathogenesis will enable novel therapeutic strategies that target the earliest molecular signature of disease.

Figure: 1.

Figure: 2.

Table 1

Recent human iPS cell-based models of cardiac channelopathies and cardiomyopathies

	Disease	Somatic Origin	Cell Product	Molecular Markers	Source
Cardiac Channelopathy	LQTS1	Dermal Fibroblasts	Beating CMs	ACTN2, TNNT2, MYL2, MYL7, HCN4	[20]
		Dermal Fibroblasts	Beating CMs	ACTN2, TNNT2, MYH6, NKX2.5, GATA4, TBX5, ANP, KCNQ1, KCNH2	[21]
		Dermal Fibroblasts	Beating CMs	ACTN2, TNNT2, CACNA1C, NFATC4, ANP, SCN5A, K ⁺ channel genes	[22]
		Dermal Fibroblasts	Beating CMs	TNNI3	[23]
	LQTS2	Dermal Fibroblasts	Beating CMs	ACTN2, TNNI3	[24]
		Dermal Fibroblasts	Beating CMs	ACTN2, TNNI3, MYL2, MYH6, MYH7, NKX2.5, KCNH2, CX43	[25]
		Dermal Fibroblasts	Beating CMs	TNNT2, MYL2, MYL7, MYH7, GATA4, KCNH2, CX43	[26]
		Dermal Fibroblasts	Beating CMs	ACTN2, MYH7, TTN	[27]
	LQTS3	Dermal Fibroblasts	Beating CMs	TNNT2	[28]
		Dermal Fibroblasts	Beating CMs	MYH6, MYH7, CACNA1C, RYR2, KCNQ1, SCN5A	[29]
		Dermal Fibroblasts	Beating CMs	ACTN2, TNNI3, MYL2, MYH6, MYH7, NKX2.5, RYR2	[30]
		Dermal Fibroblasts	Beating CMs	ACTN2, TNNT2, MYH6, RYR2, FKBP1B, CASQ2, ANP	[31]
	CPVT1	Dermal Fibroblasts	Beating CMs	ACTN2, TNNT2, MYL2, MYL7, ADRB1, ADRB2, Ca ²⁺ handling genes, K ⁺ Na ⁺ Cl ⁻ channel genes	[32]
		Dermal Fibroblasts	Beating CMs	ACTN2, TNNT2, RYR2, PLN, CACNA1C, SERCA, SLC8A1, CX43	[33]
		Dermal Fibroblasts	Beating CMs	ACTN2, TNNT2, TNNI3, CASQ2, CALR, RYR2, JCTN, TRDN, SERCA SLC8A1	[34]
		Dermal Fibroblasts	Beating CMs	ACTN2, TNNI3, MYL7, MYH7	[35]
	CPVT2	Dermal Fibroblasts	Beating CMs	ACTN2, TNNI3, MYL2, MYL7, KCNQ1	[36]
		Dermal Fibroblasts	Beating CMs	ACTN2, TNNI3, MYH7, ANP	[37]
		Dermal Fibroblasts	Beating CMs	TNNT2	[38]
		Dermal Fibroblasts	Beating CMs	ACTN2, TNNT2, CACNA1C, NFATC4, ANP, SCN5A, K ⁺ channel genes	[22]
Cardiomyopathy	HCM	Dermal Fibroblasts	Beating CMs	TNNT2, MYL2, MYL7, MYH6, MYH7, NFATC4, ANP	[39]
		Dermal Fibroblasts T Lymphocyte	Beating CMs	ACTN2, TNNT2, MYL2, MYL7, ANP	[40]
		Dermal Fibroblasts	Beating CMs	ACTN2, TNNT2, MYL7, CX43	[41]
		Dermal Fibroblasts	Beating CMs	ACTN2, TNNT2	[42]
	DCM	Dermal Fibroblasts	Beating CMs		
		Dermal Fibroblasts	Beating CMs		

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript

	Disease	Somatic Origin	Cell Product	Molecular Markers	Source
		Dermal Fibroblasts	Beating CMs	ACTN2	[43]
		Dermal Fibroblasts	Beating CMs	ACTN2, TNNT2, CACNA1C, NFATC4, ANP, SCN5A K ⁺ channel genes	[22]
		Dermal Fibroblasts	Beating CMs	ACTN2, TNNI3, MYL2, MYH6, MYH7, ISL1	[44]
	ARVC	Dermal Fibroblasts	Beating CMs	ACTN2, MYH7	[45]
	BTHS	Dermal Fibroblasts	Beating CMs	VCAM-1	[46]
	Pompe Disease	Dermal Fibroblasts	Beating CMs	ACTN2, TNNI3, MYH6, MYH7, NKX2.5, HAND1, ANP	[47]

Table abbreviations: Long QT Syndrome (LQTS), Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT), Jervell and Lange-Nielson Syndrome (JLNS), Hypertrophic Cardiomyopathy (HCM), Dilated Cardiomyopathy (DCM), Arrhythmicogenic Right Ventricular Cardiomyopathy (ARVC), Barth Syndrome (BTHS)